Navigation Links
Angioplasty may be feasible for liver transplantation candidates with heart disease

A small, retrospective study determined that percutaneous coronary intervention (PCI) was safe in patients with significant coronary artery disease (CAD) who were referred for liver transplantation. Larger studies are needed to determine the effectiveness of angioplasty in patients with end-stage liver disease (ESLD). Details of the study are available in the July issue of Liver Transplantation, published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

Medical evidence states that ESLD is associated with increased cardiovascular risk and CAD has been reported in up to 28% of this patient population, with those 50 years of age having the highest prevalence. Further studies have found that despite medical management or surgical revascularization, the three-year mortality of patients with CAD who receive liver transplants is 26% to 50%. Moreover, heart bypass surgery prior to transplantation can exacerbate liver failure and increase mortality risk.

"Our research is the first to demonstrate the feasibility and safety of PCI in patients with ESLD and thrombocytopenia who are candidates for liver transplantation," said Babak Azarbal, MD, interventional cardiologist at Cedars-Sinai Medical Center and lead author. In the past, PCI with stenting had not been used in patients with ESLD due to increased bleeding complications from peri- and post-procedural regimens that reduce the possibility of blood clots. These required anticoagulation and anti-platelet therapies could increase risk in ESLD patients with low platelets (thrombocytopenia) and bleeding disorders (coagulopathy).

The current study included 16 patients with ESLD who had significant CAD, but were acceptable candidates for liver transplantation. Fifteen patients underwent PCI using bare-metal stents and one patient had balloon angioplasty alone. Successful PCI was achieved in 94% of patients, with a single case of suboptimal residual stenosis following stenting. All patients remained clinically stable at one month following the intervention, with 9 patients added to the waiting list for liver transplantation and 3 who received liver transplants.

This research found PCI to be a safe and feasible option for ESLD patients with significant heart disease. Given the small sample size and retrospective nature of this study, the authors caution that their results may not be representative of the broader population of patients with ESLD and CAD. "Further investigation is needed to determine whether PCI improves clinical outcomes in ESLD patients with significant heart disease who otherwise would not be candidates for liver transplantation," concluded Antoine Hage, MD, Director of Solid Organ Transplant Cardiology at Cedars-Sinai Heart Institute in Beverly Hills, California and co-author of the study.


Contact: Dawn Peters

Related medicine news :

1. Cardiac Rehab Can Boost Survival After Angioplasty, Study Finds
2. Elevated protein levels in cardiac muscles could predict mortality following angioplasty
3. Many Heart Patients Place False Hope in Angioplasty
4. Drug trial results refine treatment during angioplasty operations
5. The Mount Sinai Hospital Earns Highest Ratings in New York State Report on Coronary Angioplasty
6. UCLA study compares bypass surgery to angioplasty
7. New Insights Into Whos At Risk With Angioplasty
8. NEJM Publishes Trial Results Demonstrating Bard FLAIR Endovascular Stent Graft Is Superior To Balloon Angioplasty For Failing Dialysis Grafts
9. Halving the radiation dose in cardiac perfusion imaging is now feasible
10. Baby-led weaning is feasible but could cause nutritional problems for minority of infants
11. Nanoparticles disguised as red blood cells will deliver cancer-fighting drugs
Post Your Comments:
(Date:11/30/2015)... , ... November 30, 2015 , ... ... continuing education course in Dallas, TX, on January 29 and 30, 2016. The ... improve the functions of their practices, to learn how to better succeed in ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... a key disease-causing component of bacteria could be effective in fighting methicillin-resistant Staphylococcus ... Georgia State University. , Their study showed that small molecule analogs that target ...
(Date:11/30/2015)... ... November 30, 2015 , ... Dr. Seth D. Margulies ... locations, patients can visit Dr. Margulies to experience the best available orthodontic experience in ... title of "NJ Top Dentist"! , Orthodontics is the branch of dentistry that specializes ...
(Date:11/30/2015)... ... 2015 , ... ”Dying Words: The AIDS Reporting of Jeff Schmalz and How ... coincide with World AIDS Day. The multi-media project will be in audio documentary form ... he was dying of the disease. , A collaborative effort led by author, professor ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... Reports magazine, quoted Michael Hansen, Ph.D., a senior scientist at Consumer Reports as ... more so for a child’s exposure limits. , The original Nov 2015 CR ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... KONG, Nov. 30, 2015 (HK$,000)For the Six Months Ended 30 September 2015 ... Income , 421,979 , 384,242 , ... , 34,719 , (18.3) Medical Insurance ... , 16.1 Medical Devices and Accessories Sales , ... Chinese Herbal Medicines Sales , 2,822 , ...
(Date:11/30/2015)... Calif. , Nov. 30, 2015 /PRNewswire/ ... the norm in U.S. medical imaging is ... increasingly popular accountable care payer-provider contracts are ... and, in their wake, alter provider-vendor relationships. ... payments will push forward new purchasing frameworks ...
(Date:11/30/2015)... Nov. 30, 2015 Oramed Pharmaceuticals Inc. (NASDAQ: ... the development of oral drug delivery systems, announced today ... at up to $50,000,000 with Hefei Tianhui Incubator of Technologies Co., Ltd. ... capsule, ORMD-0801, in China , ... . The agreements were signed at the Israel ...
Breaking Medicine Technology: